Clinical trials: Dyskinesia, Drug-Induced

Tardive Dyskinesia

Aim to Reduce Movements in Tardive Dyskinesia

• Completed
• Age: 18 to 75 years
• Phase 2/3
• Results posted

The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

Trial name

ARM-TD (NCT02195700)

Testing

SD-809

Where

41 sites in United States, Czechia and 2 more

Volunteers

117 people

Sponsor

Auspex Pharmaceuticals, Inc.